header logo image


Page 906«..1020..905906907908..920930..»

Is Stem Cell Therapy Safe and Effective? | Berkeley Wellness

February 1st, 2019 11:45 pm

Paul Knoepfler, PhD, is an associate professor at UC Davis School of Medicine with a special research interest in stem cells and cancer. In addition to his research, Dr. Knoepfler is the creator of the Knoepfler Lab Stem Cell Blog, through which he tries to inform people about legitimate stem cell research, and warn them about the rise of stem cell clinics offering unproven and sometimes risky stem cell treatments. Knoepfler is also the author of the book Stem Cells: An Insider's Guide, that examines the ethical issues and regulations surrounding stem cell transplants.

Frankly, there's a lot of stem cell snake oil out there. Weve seen a rise in stem cell tourismclinics worldwide selling treatments that are not proven safe and effective. I don't think the average patient can easily navigate the wild universe of stem cells and be confident they know whether a particular treatment would be safe and effective. Many clinics forgo the usual, accepted path of FDA pre-approval of an experimental therapy such as stem cells.

Not many. Bone marrow transplantation and hematopoietic stem cell transplants are the most established. Otherwise things are experimental and risky.

Many predatory stem cell clinics offer a whole menu of dozens of conditions for which they sell "treatments." For example, a single clinic may sell an adipose (fat) stem cell therapy for 15 conditions, none of which have anything to do with fat. The conditions may range from musculoskeletal disorders to neurological diseases to pulmonary conditionsand the doctor providing the stem cell treatment may have no expertise in those conditions.

There are many issues of concern. Some I mentioned earlier, including the lack of FDA approval, the lack of physician expertise in the area of the patient's disease, the lack of logical reason why a fat stem cell therapy would help a given condition, the lack of proper informed consent, and the lack of compelling data backing up the treatment.

Stem cells are also often administered in ways that don't make a whole lot of sense, such as intravenously (IV) for a brain condition. Stem cells can cause abnormal tissue growth thateven if benigncan be destructive to surrounding tissues. Stem cells can also cause cancer, pulmonary emboli, and immune reactions.

The FDA regulates biological drugs and products, including stem cell therapies. But the FDA does not regulate the doctors directly, as that is the responsibility of state medical boards. And the doctors at stem cell clinics are using the drugs and devices "off label" in ways that were not FDA approved. Is this illegal? We don't have a clear answer, particularly because the FDA has not taken any clear action in the last couple of years on this. (Previously the FDA had issued warnings to stem cell clinics.) The lack of FDA action has created a gray zone in which hundreds of clinics are now operating. That gray zone could suddenly collapse or instead things could stay murky for quite some time. Stuck in the middle are patients.

I recommend that patients talk to their primary care doctor about whether a stem cell therapy might be advisable or not. Patients should weigh the potential risks versus possible benefits, ideally using actual data. They should consider other options, and do as much homework as they can. Unfortunately many patients are understandably desperate for hope; predatory clinics take advantage of such patients. For many patients, cost is also an issue. A single stem cell treatment can cost $10,000, and many patients get more than one transplant. I strongly recommend against letting celebrity patients such as sports stars be the inspiration for stem cell therapy.

I noticed in late 2009 that there was a gap in the stem cell world. Social media and the Internet were dominated by the stem-cell clinic industry promoting this therapy, and by activists opposed to using stems cells from embryos for any medical reason at all. There was a need for a rational voice advocating for the stem cell field and evidenced-based medicine. I would also emphasize that there is much to be excited about with regard to stem cells and hundreds of legitimate clinical trials out there. I am hugely optimistic that stem cells will become a major part of mainstream medicine. But it is important not to jump the gun and do more harm than good by going too fast.

This opinion does not necessarily reflect the views of the UC Berkeley School of Public Health or of the Editorial Board at BerkeleyWellness.com.

See the rest here:
Is Stem Cell Therapy Safe and Effective? | Berkeley Wellness

Read More...

Stem Cell Therapy in Thailand – Beike Biotech

February 1st, 2019 11:43 pm

TREATMENT:hRPE stem cells implantation (human Retinal Pigment Epithelial cells, (adult stem cells) by stereotactic brain injection + nutritious stem cell cocktail treatment (intravenous).

START OF TREATMENT:March 6, 2007.

BEFORE THE TREATMENT: Lindas main symptoms were rigidity and stiffness in the left side of her body. She had mild tremors mainly in her left hand and had difficulty grasping small objects or holding things with her fingers. She would drag her left leg while walking and while at rest the

muscles in her leg and tows would contract. During the night her muscles would contract constantly keeping her regularly from having more than few hours sleep. Her muscles were very weak and she would tire very quickly, her posture was stooped and she suffered from a general tenseness and stiffness in her face, neck and back.

Without the affect of the medications she could not turn her neck and should turn her whole body in order to look back. Every morning, before the medications started to influence, it was difficult getting dressed, getting out of bed or taking a shower.

Before the treatment Linda took her medications every 2-3 hours (Contam 250mg x 8 times a day). One hour after taking the medications Lindas symptoms were hardly noticed, but the medications influence wear out quickly and Lindas every activity was dependant on her next dose of medications.

During the last few years Lindas short term memory was affected up to a level that she quit her job in human resources. Her hand writing was affected too even after taking the medications, it was still very scratchy and hard to read.

Linda also suffered from general anxiety and depression.

AFTER THE TREATMENT:

Lindas first notable change after the surgery was a full night sleep - the first one in 5 years. Within 5 weeks after the stem cell implantation most of Lindas symptoms were gradually gone. Her fingers got their flexibility back and the tremors were gone she could now grasp things, open a door and articulate more precise movements with her fingers.

The cramps in her leg were gone and she stopped dragging her left leg.

I dont need to think anymore about every movement, as I did before she says.

Her muscle tension was significantly reduced, she felt more relaxed and stronger than before.

Her posture became more open and she could now turn her neck more easily. Before leaving the hospital Linda still had some weakness in her muscles but she felt that she is getting stronger every day.

Linda also noticed that her sense of smell and taste that were greatly weakened during the last years were coming back.

A major change in her quality of life was that now her symptoms were unnoticeable with almost half the dosage of the medications she used to take before. Linda is now taking medications 4 times a day (Sinemet 200mg X4 times a day) instead of 8 times of double dosage that she used to take before the treatment.

I was a watch keeper, I used to watch at the clock all the time, I stopped swimming riding bicycle and other activities because I never knew when the medications affect will wear out she says.

Linda hopes that her medications could be gradually reduced even more, and she will keep a close contact with her doctors in China in order to follow up with her condition.

Read more:
Stem Cell Therapy in Thailand - Beike Biotech

Read More...

StemFit Feeder Free Culture | amsbio

February 1st, 2019 11:43 pm

StemFit is a xeno-free, defined medium proven to effectively maintain Induced Pluripotent Stem (iPS) and Embryonic Stem (ES) cells under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture. Now available in research and clinical grade formulations StemFit combines market-leading colony forming efficiency with lower than standardmedia volume consumption to offer the most cost-effective colony expansion compared to leading competitors.

Benefits:

Find out about our new StemFit and iMatrix Recombinant Laminin Coating Free protocol.

Weekend-Free Cell Culture:

Figure 1. StemFit allows flexible weekend free protocols.

Greater Than x100 Folder Expansion:

Figure 2. Human 201B7 iPSCs grown on MEFs (feeder dependent)were transitioned to feeder-freeconditions with StemFit or commerciallyavailable medium A on respective ECMs (1000cells/cm2), and cultured for one week onpre-coated plates.

Reduced Media Consumption:

Figure 3. StemFit offers unparrallel cost savings, requiring less media volume and less media changes to achieve the same expansion.

Easy Transition from Feeder to Feeder-Free Culture:

Figure 4. Schematic of the transition of 201B7 iPSCs from feeder cell conditions to feeder free using StemFit. Protocol courtesy of the Center for iPSC Research and Application, Kyoto University.

Contact Us To Request A Free Sample

Superior Colony Forming Efficiency From a Single Clone:

StemFit culture medium has been independently evaluated to offer a high rate of colony expansion ofundifferentiated iPS/ES cells, while retaining normal karyotype following long-term passage.

Figure 5. Human iPSCs were adapted to StemFit,or commercially available medium A or B onMatrigel for more than 3 passages. Then,cells were serially diluted and seeded with eachmedium on Matrigel-coated 96-well platesat 1 cell/well or 10 cells/well. The number ofseeded cells was counted after 3 hours, andcolonies were counted at day 7.

Superior Performance of StemFit for the Culture of Induced Pluripotent Stem Cells. An independant study performed by CGT Catapult.

Figure 6. Compared against the 4 leading stem cell culture media (M2 - M5), StemFit (M1) demonstrates high rates of cell growth. Densities of approx. 7x105 viable cells/cm2 (vc/cm2) were achieved with protocol M1 after a 7-day culture cycle. Thenumber of doublings per day was found to be higher in M1

Highly Stable and Reproducible Feeder-Free Culture:

Figure 7. Human 201B7 iPSCs were cultured on iMatrix Laminin-511 with StemFit for 4 weeks without weekendfeeding. Cell colonies were dissociated into single cells and seeded at the listed densities.

Citations:

Ryuji Morizane & Joseph V Bonventre (2017) Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells. Nature Protocols 12, 195207 (2017).

Miyazaki, T. et al. (2017) Efficient Adhesion Culture of Human Pluripotent Stem Cells Using Laminin Fragments in an Uncoated Manner. Scientific Reports 7: 41165.

Camp, J. G. et al. (2017) Multilineage communication regulates human liver bud development from pluripotency. Nature 2017 Jun 22;546(7659):533-538.

Nakagawa, M. et al.(2014) A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Scientific Reports. 4, Article number: 3594.

Related Products:

See the original post here:
StemFit Feeder Free Culture | amsbio

Read More...

Biotechnology – Health and Public Services Health … – About ACC

February 1st, 2019 8:47 am

The Biotechnology curriculum, which has emerged from molecular biology and chemical engineering, is designed to meet the increasing demands for skilled laboratory technicians in various fields of biological and chemical technology

Course work emphasizes biology, chemistry, mathematics, and technical communications. The curriculum objectives are designed to prepare graduates to serve as research assistants and technicians in laboratory and industrial settings and as quality control/quality assurance technicians.

See our Biotechnology Center of Excellence!

Biotechnology trains students to work as research assistants ortechnicians, within a variety of industry and researchbased settings.

Lab equipment use, calibration, and troubleshooting Bioprocessingupstream and downstreamprocessing Cell Culturebacterial, mammalian, and stem celllines Gene cloning, genetic engineering, and DNAsequencing Immunological assays, antibody production, andscreening methods

Students gain hands-on experience in a state-of-the artfacility including a cell culture lab, bioprocessing lab,and DNA lab. Each student gains extensive laboratoryskills (over 700 hours of accumulated lab time forA.A.S.) necessary to enter the workforce directly, orto continue their education elsewhere. This positionsgraduates favorably for entry level jobs with theessential skills to be successful in industry or researchsettings.

Associate in Applied Science Degree (A.A.S.)Biotechnology

CertificateBasic Laboratory TechniquesBioinformatics

Academic research labs Pharmaceutical companies Environmental testing facilities Biomanufacturing production Medical testing labs

Entry-level range: $30,000-$35,000+

North Carolina is #3 in the country with over 700biotech companies & 63,000 employees in theindustry, with an industry wide average salary of$95,000. -ncbiotech.org

For more information, call the Biotechnologydepartment at 336-506-4224.

Continue reading here:
Biotechnology - Health and Public Services Health ... - About ACC

Read More...

Biotechnology – Monsanto Africa

February 1st, 2019 8:47 am

Home > Biotechnology

Print This Page

Biotechnology is the use of living things to make or change products.

Many people see the science of biotechnology as a new and even controversial discovery. But biotechnology the genetic enhancement of agricultural products may be one of the oldest human activities. For thousands of years, from the time human communities began to settle, cultivate crops and farm the land, humans have manipulated the genetic nature of the crops and animals they raise through breeding. Breeding has been done to improve yields, enhance taste and extend growing seasons. All major crop plants, which provide 90 percent of the globe's food and energy intake, have been extensively manipulated, hybridized, inter-bred and modified over the millennia by countless generations of farmers intent on producing crops in the most efficient ways.

Modern agricultural biotechnology merely takes these breeding enhancements a step further, going directly to the plants DNA to make these enhancements more precise and easier to control. Crops resulting from modern agricultural biotechnology, which have been safely planted for more than ten years on over a billion acres.

Modern biotechnology has allowed scientists to develop a better understanding of the function, structure and evolution of plants and now, through gene technology, enabled scientists to switch off genes or copy them and move them between species.

In the case of agriculture, genes coding for specific traits are combined with existing varieties and hybrids to produce crop plants that are capable of performing even better. Good examples of these are insect protected cotton and maize, and herbicide resistant crops such as soya, maize and cotton. This technology also permits the combination of such traits into a single crop plant. In this way varieties and hybrids which are both herbicide and insect resistant are possible.

Given increasing demand for food, feed and fuel, agricultural biotechnology provides a way for farmers to produce more grain on the same amount of land, using fewer inputs. Ultimately, this technology helps farming become more sustainable. For farmers, biotech crops can reduce cost by raising yield, improving protection from insects and disease, or increasing tolerance to heat, drought and other stress. Value-added biotech traits can provide consumer benefits such as increased protein or oil, improved fatty-acid balance or carbohydrate enhancements.

The DNA (deoxyribonucleic acid) from different organisms is essentially the same simply a set of instructions that directs cells to make the proteins that are the basis of life. Whether the DNA is from a microorganism, a plant, an animal or a human, it is made from the same materials.

Throughout the years, researchers have discovered how to transfer a specific piece of DNA from one organism to another. The first step in transferring DNA is to "cut" or remove a gene segment from a chain of DNA using enzyme "scissors.

The researcher then uses the "scissors" to cut an opening in the recipient DNA where the gene is to be inserted. Because the cut ends of both the gene segment and the recipient DNA are chemically "sticky," they attach to each other, forming a chain of DNA that now contains the new gene. To complete the process, researchers use another enzyme to paste or secure the new gene in place.

Monsanto scientists pioneered the application of this technique for use in plants. Subsequent decades of research have allowed Monsanto specialists to apply their knowledge of genetics to use these biotechnology techniques to improve large-acre crops such as maize, soybeans and cotton. Our researchers work carefully to ensure that, except for the addition of a beneficial trait, improved crops are the same as current crops.

Current population growth is already straining the earth's resources. According to the U.S. Census Bureaus latest projections, the population will increase to 9 billion by 2042, up 50 percent from 1999.

Agricultural biotechnology is one important part of sustainable development, helping farmers do more with less. For example, biotech crops can increase yields without requiring any additional farmland, saving valuable rain forests and animal habitats. Other innovations can reduce or eliminate reliance on pesticides and herbicides that may contribute to environmental degradation. Still others can preserve precious soil and water resources, one day even allowing plants to thrive in times of drought, heat and poor soil quality.

An additional benefit of agricultural biotechnology is the increased adoption of conservation tillage by farmers. Conservation tillage methods leave crop mulch covering the ground between growing seasons, providing a protective cover that holds soil in place, minimizes runoff and dramatically decreases erosion.

Most experts agree that plant biotechnology is safe and effective. Working to implement new agricultural technology and the infrastructure required to meet future food needs will improve the quality of life for people worldwide for years to come.

See original here:
Biotechnology - Monsanto Africa

Read More...

Global Marine Biotechnology Market Report 2018: Drivers …

February 1st, 2019 8:47 am

DUBLIN, Jan. 31, 2019 /PRNewswire/ --

The "Marine Biotechnology - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Global Marine Biotechnology market accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during the forecast period.

Some of the important factors driving the market growth are current applications of marine derived enzymes in cosmetics, use of micro algae and marine algae in bio-field products. However, Lower R&D investment in the field is hampering the growth of the market. Some of the key opportunities is the Marine biotechnological advancements has been resulted successful in diverse fields with increasing investments from venture capitalists.

Marine biotechnology is a pioneering field of in recent science and technology that customs various marine bio resources for a huge number of uses, including the production of food, fuel, often bioactive, compounds and possibly will contribute to prosperous communities, green growth and sustainable industries. Even though marine biotechnology is in an emerging stage, it has unexploited potential and accomplished capability growth prospect for future.

By applications, Marine Natural Products for Medicine segment is held significant growth during the forecast period due to rising investment by key players and other factors like healthy and dietary supplements because they are rich in amino acids, proteins, vitamins, and minerals etc. Since the marine environment is the mainly biologically and chemically diverse habitat on the planet, marine biotechnology has, in recent years delivered an increasing number of most important therapeutic products, industrial and environmental applications and analytical tools.

By geography, Europe is anticipated to be one of the leading regions contributing to the global market during the forecast period. With Europe getting better from the economic crisis, the region has been making stable investments in marine biotechnology and is also witnessing the appearance of several small and micro and medium sized enterprise that are making major assistance to the R&D and opening of novel marine-based products. In additionally, the European Union research policy supports a number of collaborative projects in marine biotechnology.

What our report offers:

Key Topics Covered:

1 Executive Summary

2 Preface 2.1 Abstract2.2 Stake Holders2.3 Research Scope2.4 Research Methodology2.5 Research Sources

3 Market Trend Analysis 3.1 Introduction3.2 Drivers3.3 Restraints3.4 Opportunities3.5 Threats3.6 Product Analysis3.7 Technology Analysis3.8 Application Analysis3.9 End User Analysis3.10 Emerging Markets3.11 Futuristic Market Scenario

4 Porters Five Force Analysis 4.1 Bargaining power of suppliers4.2 Bargaining power of buyers4.3 Threat of substitutes4.4 Threat of new entrants4.5 Competitive rivalry

5 Global Marine Biotechnology Market, By Source 5.1 Introduction5.2 Corals and Sponges5.3 Macro Algae5.4 Marine Fungi5.5 Marine Viruses5.6 Micro Algae

6 Global Marine Biotechnology Market, By Product 6.1 Introduction6.2 Biomaterials6.3 Bioactive Substances6.4 Other Products

7 Global Marine Biotechnology Market, By Type 7.1 Introduction7.2 Marine Animal Technolog7.3 Marine Plant Technology

8 Global Marine Biotechnology Market, By Technology 8.1 Introduction8.2 Enrichment, Isolation and Cultivation of Microorganisms8.3 Culture-Independent Techniques8.4 Large Scale Implementation

9 Global Marine Biotechnology Market, By Application 9.1 Introduction9.2 Marine Aquaculture9.3 Marine Natural Products For Medicine9.4 Marine Nutraceuticals9.5 Marine Biomaterials9.6 Marine Bioenergy9.7 Marine Bioremediation9.8 Food & Feed9.9 Energy and Environment Management Products9.10 Fine Chemical9.11 Environment

10 Global Marine Biotechnology Market, By End User 10.1 Introduction10.2 Healthcare/Biotechnology10.3 Consumers Products10.4 Public Services & Infrastructure10.5 Industrial Products10.6 Pharmaceuticals10.7 Supplements10.8 Cosmetics

11 Global Marine Biotechnology Market, By Geography 11.1 Introduction11.2 North America11.3 Europe11.4 Asia Pacific11.5 South America11.6 Middle East & Africa

12 Key Developments 12.1 Agreements, Partnerships, Collaborations and Joint Ventures12.2 Acquisitions & Mergers12.3 New Product Launch12.4 Expansions12.5 Other Key Strategies

13 Company Profiling

For more information about this report visit https://www.researchandmarkets.com/research/jsv93b/global_marine?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View original post here:
Global Marine Biotechnology Market Report 2018: Drivers ...

Read More...

What is Biotechnology? | School of Biotechnology | DCU

February 1st, 2019 8:47 am

Biotechnology can be defined as the controlled and deliberate manipulation of biological systems (whether living cells or cell components) for the efficient manufacture or processing of useful products. The fact that living organisms have evolved such an enormous spectrum of biological capabilities means that by choosing appropriate organisms it is possible to obtain a wide variety of substances, many of which are useful to man as food, fuel and medicines. Over the past 30 years, biologists have increasingly applied the methods of physics, chemistry and mathematics in order to gain precise knowledge, at the molecular level, of how living cells make these substances. By combining this newly-gained knowledge with the methods of engineering and science, what has emerged is the concept of biotechnology which embraces all of the above-mentioned disciplines.

Biotechnology has already begun to change traditional industries such as food processing and fermentation. It has also given rise to the development of a whole new technology for industrial production of hormones, antibiotics and other chemicals, food and energy sources and processing of waste materials. This industry must be staffed by trained biotechnologists who not only have a sound basis of biological knowledge, but a thorough grounding in engineering methods. At Dublin City University, the School of Biological Sciences is unique in having, as members of its academic staff, engineers who have specialised in biotechnology. The degree programme also places a major emphasis on practical work and on developing a wide range of analytical and manipulative skills, including pilot plant operational skills appropriate to the biotechnologist. Graduates will be in an ideal position to exploit the opportunities for biotechnology in Ireland, in established or developing companies.

The course encompases biological and engineering aspects

For more information on the BSc in Biotechnology

Read the original post:
What is Biotechnology? | School of Biotechnology | DCU

Read More...

Biotechnology Facts – Softschools.com

February 1st, 2019 8:47 am

Biotechnology is not a new field, although its intentional use is comparatively new. Humans have unknowingly used biotechnology practices for thousands of years, specifically in farming and pharmaceuticals. Even in the Neolithic period, early humans incorporated a very broad definition of biotechnology in their newfound agricultural attempts. By the broad definition of the field, early civilizations' brewing and fermenting of alcohol, specifically by the Egyptians, Chinese, and Indians, and the use of yeast in bread making by many civilizations would fall under biotechnology. The term "biotechnology" is thought to have been first used in 1919 by Karoly Ereky. As new practices in biotechnology occur, additional subfields of the science have been created, including genomics, gene therapy, immunology, and more. By some standards, early practices in farming that utilized selective breeding could also be considered biotechnology. Perhaps the most crucial application of biotechnology of its era was the production of antibiotics to fight infection. Even today, researchers are continuing to improve upon biofuels in order to cut down on fossil fuel mining and greenhouse gas emissions. There are four major areas of biotechnology study and application. These are medical, agriculture, non-food agriculture, and environmental applications. While pharmaceuticals like antibiotics, insulin, and vaccines can be considered biotechnology uses, innovations like gene therapy and gene suppression would also meet that definition. Non-food agriculture uses apply to things like the creation of plants to produce plastics, and enzymes or single-celled organisms for industrial fermentation and the production of textiles. Some environmental applications of biotechnology include uses microbes to clean up an oil spill or fungal or algae outbreak. Through the efforts of the US Congress and the National Institute of General Medical Sciences under the National Institutes of Health, biotechnology has become a sought-after field of study in many major universities. Biotechnology does have its critics, as there is currently a movement to ban and avoid genetically modified foods grown through genetically altered agriculture. A labeling system was implemented in the US that requires genetically altered produce to be labeled as such.

Read the rest here:
Biotechnology Facts - Softschools.com

Read More...

Master of Science in Biotechnology – Drexel University …

February 1st, 2019 8:47 am

Biotechnology is the use of living organisms, or products of living organisms, for human benefit, and it has had a tremendous impact on many aspects of modern life. Its effects, however, are perhaps most keenly felt within the food/agricultural and medical fields. Biotechnological processes are used in the production of specific foods and have allowed the genetic modification of food crops to be hardier and to have increased nutritional value. The health care sector likewise has benefited from biotechnology to produce medicines and vaccines that prevent or cure disease. Moreover, biotechnological theory and methodologies will be central to the realization of personalized medicine.

At Drexel University, we are proud to offer the Master of Science in Biotechnology (BIOT), an innovative, non-thesis graduate degree program that emphasizes hands-on training in state-of-the-art laboratory techniques used across the biotechnology and biomedical industries.

This program furnishes students with the necessary technical skills to successfully seek gainful employment in both biotechnology/pharmaceutical firms and academic laboratories. It does so by using a two-pronged approach that combines theory with hands-on instruction under the direct supervision of our diverse and accomplished research faculty. The program is appropriate for recent college graduates or experienced technicians wishing to bolster their methodological base.

The Master of Science in Biotechnology program is ideally suited for enhancing the scientific skill set of the following groups:

"The Biotechnology master's program provided me with an excellent opportunity to gain a diverse set of technical skills, including those in biochemistry, biophysics and molecular biology, while exploring multiple areas of biomedical research. In addition, the experienced principal investigators and accelerated course work strengthened the knowledge I had gained throughout undergrad. Overall, the programs productive and focused curriculum at both the bench and in the classroom left me well qualified for positions in both academia and industry. On the strength of the Biotechnology Master of Science program at Drexel University, I have successfully secured positions in local biotech/pharma, and now work in the Screening Group at Janssen R&D (Johnson & Johnson) as an associate scientist."Jeff Branson, Class of 2016

The program encompasses both classes and hands-on practica. It is the inclusion of practica that makes this program unique, stressing applied learning of key methodologies used throughout academia and industry and their practical use in addressing research questions in bioscience and biomedicine. This innovative combination of technical theory and application will provide graduates of this program with a knowledge base and a set of skills that will make them very competitive for laboratory jobs in the academic or industrial sectors or enhance their potential for advancement at their current place of employment.

Swetaben Patel and Aishwarya Subramanian have taken positions at GlaxoSmithKline.

Lina Maciunas is currently pursuing a PhD at Drexel and works in the Loll Laboratory.

Jeff Branson is currently working as an associate scientist at Janssen R&D (Johnson & Johnson) in the Screening Group.

Ayonika Mukherjee has an internship at GlaxoSmithKline.

See the original post here:
Master of Science in Biotechnology - Drexel University ...

Read More...

Biotechnology – PRIDCO

February 1st, 2019 8:47 am

Puerto Rico. The Bio Island.

Puerto Rico enjoys a long legacy in pharmaceutical and medical device manufacturing. Biologics are also a growing segment of the island's life sciences sector. Amgen, Eli Lilly, Abbott and Becton Dickinson Bioscience alone have invested more than $65.9 million in four plants since 2005. Puerto Rico also boasts the world's largest modular biotechnology plant for producing recombinant human insulin.

Growing Agricultural Biotechnology Sector

Puerto Rico has also emerged as an important center for agricultural biotechnology. Pioneer Hi-Bred, BASF Agrochemical, Bayer-Cropscience, Syngenta Seeds and Rice Tec are among many seed companies that have found the island to be fertile ground for R&D with our tropical weather, consistent water supply, ease of commerce with the U.S., attractive incentives and top-quality agricultural science talent.

A Highly Educated Workforce

Puerto Rico's workforce has vast knowledge in GMP, FDA and other global regulations, while the island's university system turns out a steady stream of new talent:

Helpful Links:

Read more from the original source:
Biotechnology - PRIDCO

Read More...

Stem Cell Therapy in india – Stem Cell Treatment in Uttar …

February 1st, 2019 8:43 am

Welcome to Stem Cell Consults

Stem Cell Center offers a complete scope of stem cell solutions in India for the treatment of various types of diseases. Our main focus is helping people get back to good health through stem cell treatment. Our organization associated with so many hospitals, medical tourism company and also has our own stem cell research labs in India to provide best quality of stem cells in this advanced stem cell treatment field to provide best quality of treatment for all needed patients al over the world.

We also provide complete stem cell lab set up in all over the world and started some other stem cells labs in other countries via our best and experienced team. We have more than 10 years stem cell research experience and treated more than thousand patients for various diseases and even provide stem cell services to various hospitals in all over the world.

We at stem cell center can proudly say that we give the best stem cells in India. Our years of research, hard work and trials have helped us pioneer and accomplish amazing results when required. Your precious cells are processed utilizing our restrictive technology to guarantee they have the best features required for treatment. Undeveloped cell focus are completely anchored, non-lethal and totally without reactions with an excellent probability of homing and tissue or organ.

We are giving advanced Stem Cell Therapy in India where all other medical treatment fail then this stem cell treatment apply to cure such non-treatable maladies or diseases.

As the main healthcare consultant, stem cell center in India takes care of each and every section of the Medical Tourism Trip to entire India. We guarantee, our patients get the best healthcare service by getting in place, the renowned specialty hospitals, latest stem cell treatments, economical housing and alternatives for the patients.

Our organization is giving best stem cell therapy in India and furthermore has perfection in stem cell treatment in Uttar Pradesh, Delhi NCR and all other all major cities of India for the required patients in all those application which can treat by stem cell therapy. We have stem cells in various forms to improve the better recuperation of patient and refer the best stem cell solutions after the evaluation of patient case study by our experts. Our experts in stem cell cooperate with patients however the total understanding to offer you more peace of mind to develop clear evidence based path. We have highly experts in our team and our experts are strong in research and clinical research from the two perspectives.

Our mission is to offer best stem cell therapy at sensible price not only in India but also throughout the entire world so that every required patients can get best stem cell therapy to enhance his life.

Read the original post:
Stem Cell Therapy in india - Stem Cell Treatment in Uttar ...

Read More...

Stem Cells Definition | Understanding Stem Cells …

January 31st, 2019 2:46 am

*Post also available in: Espaol Romn

Stem cells can multiply (self-renew) and differentiate into every cell within the human body, giving them enormous potential for use in regenerative medicine.

In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult humans, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Stem cell research has been going on for over 50 years because stem cells have a unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to become a wide variety of tissue types, which gives them enormous potential for use as living cell therapies.

In this article:

Several broad categories of stem cells exist, including:

Originally, all stem cells were classified as either adult stem cells or embryonic stem cells (ESCs). However, a diverse range of stem cell types has since been identified. When iPS cells were discovered in 2006, the research community had a new stem cell type that possessed most of the characteristics of ESCs without the controversy.

To make things simple, apply these definitions to classify stem cells by when they are collected during the human lifecycle:

To understand the functional potential of each stem cell type, scientists like to describe to what degree each stem cell type can differentiate into other cell types.

When assessing the functional potential of stem cells, use the following definitions:

Human embryonic stem cells (hESCs) are totipotent cells that are derived from embryos that have been createdin vitroat fertility clinics with informed donor consent. Embryonic stem cells are typically collected shortly after fertilization (within 4-5 days). At 5-6 days post-fertilization, embryonic stem cells begin to specialize, at which point they become pluripotent or multipotent cells.

Pluripotent and multipotent stem cells have a more limited differentiation capacity than totipotent stem cells.For example, multipotent blood stem cells can differentiate into red cells, white cells, and platelets in the blood, but they cannot become any cell type.

The precisepointat which a stem cell switches from a totipotent stem cell to a pluripotent or multipotent stem cell is often unclear. Furthermore, iPS cell technology allows us to reverse mature cell types back into a totipotent state. iPS cells are totipotent, so stem cells can now be collected at any point in the human lifecycle.

Today, most clinics that offer stem cell treatments administer mesenchymal stem cells (MSCs), which they source from fat tissue orbone marrow. Mesenchymal stem cells are a type of multipotent stem cell that is being explored for use in the orthopedic repair, pain management, arthritis, asthma, and many other applications. MSCs tend to exert effects on other cells and tissues within the human body, which is called paracrine signaling.

Although risks will exist whenever cell therapies are administered to humans, a large body of scientific evidence suggests that MSCs can be safe for patient use when properly administered and monitored.There is an additional layer of safety that occurs when cells are multipotent (limited in their differentiation capacity). Often, it is safer for them to be self-derived (autologous), rather than from someone else (allogeneic).

Another stem cell type that is commonly used is the hematopoietic stem cell (HSC). HSC transplantation has been used for decades as a means of rebuilding the immune system after a patient undergoes radiation or chemotherapy.

There are many companies working to introduce legitimate stem cell therapies into clinical practice. Unfortunately, there are also unregulated stem cell groups that are offering unverified and unsafe stem cell therapies to patients.

One of the risks of totipotent stem cells (embryonic stem cells and iPS cells) is that they have the potential to produce uncontrolled proliferation. The biggest concern surrounding the clinical application of these cells is their tendency to form tumors. Pluripotent and multipotent stem cells have a lower risk of producing tumor formation, but can potentially create growth of the wrong tissue type for a given location within the human body. Additionally, iPS cells are artificially manipulated in a laboratory process, so there is the possibility that the cells can act in unexpected ways.

Because many of these risks can be mitigated and monitored, stem cells are currently being investigated in hundreds of clinical trials worldwide. The majority of these clinical trials involve the use of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs). Approximately three-quarters of these stem cell trials worldwide are registered at ClinicalTrials.gov. You can screen that public database to search for trials by condition, disease, location, or sponsor. Additional trials can be found on a country-by-country basis.

To make things more complex, the U.S. FDA regulates stem cell treatments as two different types, commonly called 361 and 351 products:

To share your own knowledge or experience with stem cells, comment below.

Up Next: Advanced Dental Care: Guide To Dental Stem Cell Companies

If you need this information on the go, download your free PDF Fact Sheet below.

Stem Cells Definition | Understanding Stem Cells

Read this article:
Stem Cells Definition | Understanding Stem Cells ...

Read More...

Adult stem cell – Wikipedia

January 31st, 2019 2:46 am

Adult stem cells are undifferentiated cells, found throughout the body after development, that multiply by cell division to replenish dying cells and regenerate damaged tissues. Also known as somatic stem cells (from Greek , meaning of the body), they can be found in juvenile as well as adult animals and humans, unlike embryonic stem cells.

Scientific interest in adult stem cells is centered on their ability to divide or self-renew indefinitely, and generate all the cell types of the organ from which they originate, potentially regenerating the entire organ from a few cells.[1] Unlike for embryonic stem cells, the use of human adult stem cells in research and therapy is not considered to be controversial, as they are derived from adult tissue samples rather than human embryos designated for scientific research. They have mainly been studied in humans and model organisms such as mice and rats.

A stem cell possesses two properties:

Hematopoietic stem cells are found in the bone marrow and umbilical cord blood and give rise to all the blood cell types.[3]

Mammary stem cells provide the source of cells for growth of the mammary gland during puberty and gestation and play an important role in carcinogenesis of the breast.[4] Mammary stem cells have been isolated from human and mouse tissue as well as from cell lines derived from the mammary gland. Single such cells can give rise to both the luminal and myoepithelial cell types of the gland, and have been shown to have the ability to regenerate the entire organ in mice.[4]

Intestinal stem cells divide continuously throughout life and use a complex genetic program to produce the cells lining the surface of the small and large intestines.[5] Intestinal stem cells reside near the base of the stem cell niche, called the crypts of Lieberkuhn. Intestinal stem cells are probably the source of most cancers of the small intestine and colon.[6]

Mesenchymal stem cells (MSCs) are of stromal origin and may differentiate into a variety of tissues. MSCs have been isolated from placenta, adipose tissue, lung, bone marrow and blood, Wharton's jelly from the umbilical cord,[7] and teeth (perivascular niche of dental pulp and periodontal ligament).[8] MSCs are attractive for clinical therapy due to their ability to differentiate, provide trophic support, and modulate innate immune response.[7] These cells have the ability to differentiate into various cell types such as osteoblasts, chondroblasts, adipocytes, neuroectodermal cells, and hepatocytes.[9] Bioactive mediators that favor local cell growth are also secreted by MSCs. Anti-inflammatory effects on the local microenvironment, which promote tissue healing, are also observed. The inflammatory response can be modulated by adipose-derived regenerative cells (ADRC) including mesenchymal stem cells and regulatory T-lymphocytes. The mesenchymal stem cells thus alter the outcome of the immune response by changing the cytokine secretion of dendritic and T-cell subsets. This results in a shift from a pro-inflammatory environment to an anti-inflammatory or tolerant cell environment.[10][11]

Endothelial stem cells are one of the three types of multipotent stem cells found in the bone marrow. They are a rare and controversial group with the ability to differentiate into endothelial cells, the cells that line blood vessels.

The existence of stem cells in the adult brain has been postulated following the discovery that the process of neurogenesis, the birth of new neurons, continues into adulthood in rats.[12] The presence of stem cells in the mature primate brain was first reported in 1967.[13] It has since been shown that new neurons are generated in adult mice, songbirds and primates, including humans. Normally, adult neurogenesis is restricted to two areas of the brain the subventricular zone, which lines the lateral ventricles, and the dentate gyrus of the hippocampal formation.[14] Although the generation of new neurons in the hippocampus is well established, the presence of true self-renewing stem cells there has been debated.[15] Under certain circumstances, such as following tissue damage in ischemia, neurogenesis can be induced in other brain regions, including the neocortex.

Neural stem cells are commonly cultured in vitro as so called neurospheres floating heterogeneous aggregates of cells, containing a large proportion of stem cells.[16] They can be propagated for extended periods of time and differentiated into both neuronal and glia cells, and therefore behave as stem cells. However, some recent studies suggest that this behaviour is induced by the culture conditions in progenitor cells, the progeny of stem cell division that normally undergo a strictly limited number of replication cycles in vivo.[17] Furthermore, neurosphere-derived cells do not behave as stem cells when transplanted back into the brain.[18]

Neural stem cells share many properties with haematopoietic stem cells (HSCs). Remarkably, when injected into the blood, neurosphere-derived cells differentiate into various cell types of the immune system.[19]

Olfactory adult stem cells have been successfully harvested from the human olfactory mucosa cells, which are found in the lining of the nose and are involved in the sense of smell.[20] If they are given the right chemical environment these cells have the same ability as embryonic stem cells to develop into many different cell types. Olfactory stem cells hold the potential for therapeutic applications and, in contrast to neural stem cells, can be harvested with ease without harm to the patient. This means they can be easily obtained from all individuals, including older patients who might be most in need of stem cell therapies.

Hair follicles contain two types of stem cells, one of which appears to represent a remnant of the stem cells of the embryonic neural crest. Similar cells have been found in the gastrointestinal tract, sciatic nerve, cardiac outflow tract and spinal and sympathetic ganglia. These cells can generate neurons, Schwann cells, myofibroblast, chondrocytes and melanocytes.[21][22]

Multipotent stem cells with a claimed equivalency to embryonic stem cells have been derived from spermatogonial progenitor cells found in the testicles of laboratory mice by scientists in Germany[23][24][25] and the United States,[26][27][28][29] and, a year later, researchers from Germany and the United Kingdom confirmed the same capability using cells from the testicles of humans.[30] The extracted stem cells are known as human adult germline stem cells (GSCs)[31]

Multipotent stem cells have also been derived from germ cells found in human testicles.[32]

To ensure self-renewal, stem cells undergo two types of cell division (see Stem cell division and differentiation diagram). Symmetric division gives rise to two identical daughter cells, both endowed with stem cell properties, whereas asymmetric division produces only one stem cell and a progenitor cell with limited self-renewal potential. Progenitors can go through several rounds of cell division before finally differentiating into a mature cell. It is believed that the molecular distinction between symmetric and asymmetric divisions lies in differential segregation of cell membrane proteins (such as receptors) between the daughter cells.

Discoveries in recent years have suggested that adult stem cells might have the ability to differentiate into cell types from different germ layers. For instance, neural stem cells from the brain, which are derived from ectoderm, can differentiate into ectoderm, mesoderm, and endoderm.[33] Stem cells from the bone marrow, which is derived from mesoderm, can differentiate into liver, lung, GI tract and skin, which are derived from endoderm and mesoderm.[34] This phenomenon is referred to as stem cell transdifferentiation or plasticity. It can be induced by modifying the growth medium when stem cells are cultured in vitro or transplanting them to an organ of the body different from the one they were originally isolated from. There is yet no consensus among biologists on the prevalence and physiological and therapeutic relevance of stem cell plasticity. More recent findings suggest that pluripotent stem cells may reside in blood and adult tissues in a dormant state.[35] These cells are referred to as "Blastomere Like Stem Cells"[36] and "very small embryonic like" "VSEL" stem cells, and display pluripotency in vitro.[35] As BLSC's and VSEL cells are present in virtually all adult tissues, including lung, brain, kidneys, muscles, and pancreas[37] Co-purification of BLSC's and VSEL cells with other populations of adult stem cells may explain the apparent pluripotency of adult stem cell populations. However, recent studies have shown that both human and murine VSEL cells lack stem cell characteristics and are not pluripotent.[38][39][40][41]

Stem cell function becomes impaired with age, and this contributes to progressive deterioration of tissue maintenance and repair.[42] A likely important cause of increasing stem cell dysfunction is age-dependent accumulation of DNA damage in both stem cells and the cells that comprise the stem cell environment.[42] (See also DNA damage theory of aging.)

Adult stem cells can, however, be artificially reverted to a state where they behave like embryonic stem cells (including the associated DNA repair mechanisms). This was done with mice as early as 2006[43] with future prospects to slow down human aging substantially. Such cells are one of the various classes of induced stem cells.

Adult stem cell research has been focused on uncovering the general molecular mechanisms that control their self-renewal and differentiation.

Adult stem cell treatments have been used for many years to successfully treat leukemia and related bone/blood cancers utilizing bone marrow transplants.[47] The use of adult stem cells in research and therapy is not considered as controversial as the use of embryonic stem cells, because the production of adult stem cells does not require the destruction of an embryo.

Early regenerative applications of adult stem cells has focused on intravenous delivery of blood progenitors known as Hematopetic Stem Cells (HSC's). CD34+ hematopoietic Stem Cells have been clinically applied to treat various diseases including spinal cord injury,[48] liver cirrhosis [49] and Peripheral Vascular disease.[50] Research has shown that CD34+ hematopoietic Stem Cells are relatively more numerous in men than in women of reproductive age group among spinal cord Injury victims.[51] Other early commercial applications have focused on Mesenchymal Stem Cells (MSCs). For both cell lines, direct injection or placement of cells into a site in need of repair may be the preferred method of treatment, as vascular delivery suffers from a "pulmonary first pass effect" where intravenous injected cells are sequestered in the lungs.[52] Clinical case reports in orthopedic applications have been published. Wakitani has published a small case series of nine defects in five knees involving surgical transplantation of mesenchymal stem cells with coverage of the treated chondral defects.[53] Centeno et al. have reported high field MRI evidence of increased cartilage and meniscus volume in individual human clinical subjects as well as a large n=227 safety study.[54][55][56][57] Many other stem cell based treatments are operating outside the US, with much controversy being reported regarding these treatments as some feel more regulation is needed as clinics tend to exaggerate claims of success and minimize or omit risks.[58]

The therapeutic potential of adult stem cells is the focus of much scientific research, due to their ability to be harvested from the parent body that is females during the delivery.[59][60][61] In common with embryonic stem cells, adult stem cells have the ability to differentiate into more than one cell type, but unlike the former they are often restricted to certain types or "lineages". The ability of a differentiated stem cell of one lineage to produce cells of a different lineage is called transdifferentiation. Some types of adult stem cells are more capable of transdifferentiation than others, but for many there is no evidence that such a transformation is possible. Consequently, adult stem therapies require a stem cell source of the specific lineage needed, and harvesting and/or culturing them up to the numbers required is a challenge.[62][63] Additionally, cues from the immediate environment (including how stiff or porous the surrounding structure/extracellular matrix is) can alter or enhance the fate and differentiation of the stem cells.[64]

Pluripotent stem cells, i.e. cells that can give rise to any fetal or adult cell type, can be found in a number of tissues, including umbilical cord blood.[65] Using genetic reprogramming, pluripotent stem cells equivalent to embryonic stem cells have been derived from human adult skin tissue.[66][67][68][69][70] Other adult stem cells are multipotent, meaning they are restricted in the types of cell they can become, and are generally referred to by their tissue origin (such as mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, etc.).[71][72] A great deal of adult stem cell research has focused on investigating their capacity to divide or self-renew indefinitely, and their potential for differentiation.[73] In mice, pluripotent stem cells can be directly generated from adult fibroblast cultures.[74]

In recent years, acceptance of the concept of adult stem cells has increased. There is now a hypothesis that stem cells reside in many adult tissues and that these unique reservoirs of cells not only are responsible for the normal reparative and regenerative processes but are also considered to be a prime target for genetic and epigenetic changes, culminating in many abnormal conditions including cancer.[75][76] (See cancer stem cell for more details.)

Adult stem cells express transporters of the ATP-binding cassette family that actively pump a diversity of organic molecules out of the cell.[77] Many pharmaceuticals are exported by these transporters conferring multidrug resistance onto the cell. This complicates the design of drugs, for instance neural stem cell targeted therapies for the treatment of clinical depression.

Read more:
Adult stem cell - Wikipedia

Read More...

Nanomedicine | medicine | Britannica.com

January 31st, 2019 2:45 am

Nanomedicine, branch of medicine that seeks to apply nanotechnologythat is, the manipulation and manufacture of materials and devices that are smaller than 1 nanometre [0.0000001 cm] in sizeto the prevention of disease and to imaging, diagnosis, monitoring, treatment, repair, and regeneration of biological systems.

Although nanomedicine remains in its early stages, a number of nanomedical applications have been developed. Research thus far has focused on the development of biosensors to aid in diagnostics and vehicles to administer vaccines, medications, and genetic therapy, including the development of nanocapsules to aid in cancer treatment.

An offshoot of nanotechnology, nanomedicine is an emerging field and had garnered interest as a site for global research and development, which gives the field academic and commercial legitimacy. Funding for nanomedicine research comes both from public and private sources, and the leading investors are the United States, the United Kingdom, Germany, and Japan. In terms of the volume of nanomedicine research, these countries are joined by China, France, India, Brazil, Russia, and India.

Working at the molecular-size scale, nanomedicine is animated with promises of the seamless integration of biology and technology, the eradication of disease through personalized medicine, targeted drug delivery, regenerative medicine, as well as nanomachinery that can substitute portions of cells. Although many of these visions may not come to fruition, some nanomedicine applications have become reality, with the potential to radically transform the practice of medicine, as well as current understandings of the health, disease, and biologyissues that are of vital importance for contemporary societies. The fields global market share totalled some $78 billion dollars in 2012, driven by technological advancements. By the end of the decade, the market is expected to grow to nearly $200 billion.

Nanomedicine derives much of its rhetorical, technological, and scientific strength from the scale on which it operates (1 to 100 nanometers), the size of molecules and biochemical functions. The term nanomedicine emerged in 1999, the year when American scientist Robert A. Freitas Jr. published Nanomedicine: Basic Capabilities, the first of two volumes he dedicated to the subject.

Extending American scientist K. Eric Drexlers vision of molecular assemblers with respect to nanotechnology, nanomedicine was depicted as facilitating the creation of nanobot devices (nanoscale-sized automatons) that would navigate the human body searching for and clearing disease. Although much of this compelling imagery still remains unrealized, it underscores the underlying vision of doctors being able to search and destroy diseased cells, or of nanomachines that substitute biological parts, which still drives portrayals of the field. Such illustrations remain integral to the field, being used by scientists, funding agencies, and the media alike.

Attesting to the fields actuality are numerous dedicated scientific and industry-oriented conferences, peer-reviewed scientific journals, professional societies, and a growing number of companies. However, nanomedicines identity, scope, and goals are a matter of controversy. In 2006, for instance, the prestigious journal Nature Materials discussed the ongoing struggle of policy makers to understand if nanomedicine is a rhetorical issue or a solution to a real problem. This ambivalence is reflected in the numerous definitions of nanomedicine that can be found in scientific literature, that range from complicated drugs to the above mentioned nanobots. Despite the lack of a shared definition, there is a general agreement that nanomedicine entails the application of nanotechnology in medicine and that it will profoundly impact medical practice.

A further topic of debate is nanomedicines genealogy, in particular its connections to molecular medicine and nanotechnology. The case of nanotechnology is exemplary: on one hand, its potentialin terms of science but also in regard to funding and recognitionis often mobilized by nanomedicine proponents; on the other, there is an attempt to distance nanomedicine from nanotechnology, for fear of being damaged by the perceived hype that surrounds it. The push is then for nanomedicine to emerge not as a subdiscipline of nanotechnology but as a parallel field.

Although nanomedicine research and development is actively pursued in numerous countries, the United States, the EU (particularly Germany), and Japan have made significant contributions from the fields outset. This is reflected both in the number of articles published and in that of patents filed, both of which have grown exponentially since 2004. By 2012, however, nanomedicine research in China grew with respect to publications in the field, and the country ranked second only to the United States in the number of research articles published.

In 2004, two U.S. funding agenciesthe National Institutes of Health and the National Cancer Instituteidentified nanomedicine as a priority research area allocating $144 million and $80 million, respectively, to its study. In the EU meanwhile, public granting institutions did not formally recognize nanomedicine as a field, providing instead funding for research that falls under the headers of nanotechnology and health. Such lack of coordination had been the target of critiques by the European Science Foundation (ESF), warning that it would result in lost medical benefits. In spite of this, the EU ranked first in number of nanomedicine articles published and in 2007 the Seventh Framework Programme (FP7) allocated 250 million to nanomedicine research. Such work has also been heavily funded by the private sector. A study led by the European Science and Technology Observatory found that over 200 European companies were researching and developing nanomedicine applications, many of which were coordinating their efforts.

Much of nanomedicine research is application oriented, emphasizing methods to transfer it from the laboratory to the bedside. In 2005 the ESF pointed to four main subfields in nanomedicine research: analytical tools and nanoimaging, nanomaterials and nanodevices, novel therapeutics and drug delivery systems, and clinical, regulatory, and toxicological issues. Research in analytical tools and nanoimaging seeks to develop noninvasive, reliable, cheap, and highly sensitive tools for in vivo diagnosis and visualization. The ultimate goal is to create fully functional mobile sensors that can be remotely controlled to conduct in vivo, real-time analysis. Research on nanomaterials and nanodevices aims to improve the biocompatibility and mechanical properties of biomaterials used in medicine, so as to create safer implants, substitute damaged cell parts, or stimulate cell growth for tissue engineering and regeneration, to name a few. Work in novel therapeutics and drug delivery systems strives to develop and design nanoparticles and nanostructures that are noninvasive and can target specific diseases, as well as cross biological barriers. Allied with very precise means for diagnosis, these drug delivery systems would enable equally precise site-specific therapeutics and fewer side effects. The area of drug delivery accounts for a large portion of nanomedicines scientific publications.

Finally, the subfield of clinical, regulatory, and toxicological issues lumps together research that examines the field as a whole. Questions of safety and toxicology are prevalent, an issue that is all the more important given that nanomedicine entails introducing newly engineered nanoscale particles, materials, and devices into the human body. Regulatory issues revolve around the management of this newness, with some defending the need for new regulation, and others the ability of systems to deal with it. This subfield should also include other research by social scientists and humanists, namely on the ethics of nanomedicine.

Combined, these subfields build a case for preventive medicine and personalized medicine. Building upon genomics, personalized medicine envisions the possibility of individually tailored diagnostics and therapeutics. Preventive medicine takes this notion further, conjuring the possibility of treating a disease before it manifests itself. If realized, such shifts would have radical impacts on understandings of health, embodiment, and personhood. Questions remain concerning the cost and accessibility of nanomedicine and also about the consequences of diagnostics based on risk propensity or that lack a cure.

More:
Nanomedicine | medicine | Britannica.com

Read More...

Precision Medicine Executive Summit: Cutting-edge Insights

January 31st, 2019 2:45 am

Our 2018 conference featured keynote address by JeffreyR. Balser, M.D., Ph.D.,President and CEO, Vanderbilt University Medical Centerand Dean of the Vanderbilt University School of Medicine,one of the most progressive and innovative health systems in the country.

CEOs and administrators at the nations leading health networks and hospitals recognize this truth: precision medicine is poised to transform clinical care in ways that experts say will be highly disruptive to health networks, particularly those that are slow to respond to thisimportant trend.

That makes it imperative for CEOs and senior administrators at health networks everywhere to get answers to these two questions:1) How is precision medicine now changing clinical care today, including specific programs already used by networks and physicians to improve patient outcomes, reduce costs, and open the door to new sourcesof revenue?2) What precision medicine strategy is best for my health network and its hospitals?

Attendees will find answers to both questions at our Precision Medicine Institute Symposium 2019, taking place Thursday and Friday, May 2-3 at the Sheraton Hotel in New Orleans, LA.

During this intensive 1 1/2 day conference, the nations first movers and early adopters will discuss their first programs to infuse precision medicine into specific areas of clinical care. On topics ranging from spectacular success in oncology and cancer care, offering patients access to pharmacogenetic testing in primary care settings, and more, youll hear sessions and speakers with up-to-the minute insights so needed to develop the right precision medicine strategy for todays health networks.

Precision medicine is becoming real. It's no longer something for an egghead institution to dabble in. It can be used as a strategic advantage in terms of delivering efficient care, competing with other health systems, ways of making sure that patients are having as much risk mitigated as possible. It's an ideal opportunity to really fine-tune a health system. a really engaged audience and the type you don't normally get to speak with. Having leadership at health systems, at health companies, at other types of health enterprises, you have a different type of thinking. The networking is strong.

Howard McCloud, MDMedical Director, Personalized MedicineMoffitt Cancer Center, Tampa, FL

See All Testimonials

See the original post:
Precision Medicine Executive Summit: Cutting-edge Insights

Read More...

Where Do Stem Cells Come From? | Basics Of Stem Cell …

January 31st, 2019 2:44 am

Where do stem cells come from? Learn the basics of master cells to better understand their therapeutic potential.

In this article:

Where do stem cells come from? You have probably heard of thewonders of stem cell therapy. Not only do stem cells make research for future scientific breakthroughs possible, but they also provide the basis for many medical treatments today. So, where exactly are they from, and how are they different from regular cells? The answer depends on the types of stem cells in question.

There are two main types of stem cells adult and embryonic:

Beyond the two broader categories, there are sub-categories. Each has its own characteristics. For researchers, the different types of stem cells serve specific purposes.

Many tissues throughout the adult human body contain stem cells. Scientists previously believed adult stem cells to be inferior to human embryonic stem cells for therapeutic purposes. Theydid not believe adult stem cells to be as versatile as embryonic stem cells (ESCs), because they are not capable of becoming all 200 cell types within the human body.

While this theoryhas notbeen entirely disproved, encouraging evidence suggests that adult stem cells can develop into a variety of new types of cells. They can also affect repair through other mechanisms.

In August 2017, the number of stem cell publications registered in PubMed, a government database, surpassed 300,000. Stem cells are also being explored in over 4,600 cell therapy clinical trials worldwide. Some of the earliest forms of adult stem cell use include bone marrow and umbilical cord blood transplantation.

It should be noted that while the term adult stem cell is used for this type of cell, it is not descriptive of age, because adult stem cells can come from children. The term simply helps to differentiate stem cells derived from living humans as opposed to embryonic stem cells.

Embryonic stem cells are controversial because they are made from embryos that are created but not used by fertility clinics.

Because adult stem cells are somewhat limited in the cell types they can become, scientists developed a way to genetically reprogram cells into what is called an inducedpluripotent stem cell or iPS cell. In creating inducedpluripotent stem cells, researchers hope to blend the usefulness of adult stem cells with the promise of embryonic stem cells.

Both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are known as pluripotent stem cells.

Pluripotent stem cells are a type of cell that has the capacity to divide indefinitely and create any cell found within the three germ layers of an organism: ectoderm (cells forming the skin and nervous system), endoderm (cells forming pancreas, liver, endocrine gland, and gastrointestinal and respiratory tracts), and mesoderm (cells forming connective tissues, and other related tissues, muscles, bones, most of the circulatory system, and cartilage).

Embryonic stem cells can grow into a much wider range of cell types, but they also carry the risk of immune system rejection in patients. In contrast, adult stem cells are more plentiful, easier to harvest, and less controversial.

Embryonic stem cells come from embryos harvested shortly after fertilization (within 4-5 days). These cells are made when the blastocysts inner cell mass is transferred into a culture medium, allowing them to develop.

At 5-6 days post-fertilization, the cells within the embryo start to specialize. At this time, they no longer are able to become all of the cell types within the human body. They are no longer pluripotent.

Because they are pluripotent, embryonic stem cells can be used to generate healthy cells for disease patients. For example, they can be grown into heart cells known as cardiomyocytes. These cells may have the potential to be injected into an ailing patients heart.

Harvesting stem cells from embryos is controversial, so there are guidelines created by the National Institutes of Health (NIH) that allow the public to understand what practices are not allowed.

Scientists can harvest perinatal stem cells from a variety of tissues, but the most common sources include:

The umbilical cord attaches a mother to her fetus. It is removed after birth and is a valuable source of stem cells. The blood it contains is rich in hematopoietic stem cells (HSC). It also contains smaller quantities of another cell type known as mesenchymal stem cells (MSCs).

The placenta is a large organ that acts as a connector between the mother and the fetus. Both placental blood and tissue are also rich in stem cells.

Finally, there is amniotic fluid surrounding a baby while it is in utero. It can be harvested if a pregnant woman needs a specialized kind of test known as amniocentesis. Both amniotic fluid and tissue contain stem cells, too.

Adult stem cells are usually harvested in one of three ways:

The blood draw, known as peripheral blood stem cell donation, extracts the stem cells directly from a donors bloodstream. The bone marrow stem cells come from deep within a bone often a flat bone such as the hip. Tissue fat is extracted from a fatty area, such as the waist.

Embryonic donations are harvested from fertilized human eggs that are less than five days old. The embryos are not grown within a mothers or surrogates womb, but instead, are multiplied in a laboratory. The embryos selected for harvesting stem cell are created within invitro fertilization clinics but are not selected for implantation.

Amniotic stem cells can be harvested at the same time that doctors use a needle to withdraw amniotic fluid during a pregnant womans amniocentesis. The same fluid, after being tested to ensure the babys health, can also be used to extract stem cells.

As mentioned, there is another source for stem cells the umbilical cord. Blood cells from the umbilical cord can be harvested after a babys birth. Cells can also be extracted from the postpartumhuman placenta, which is typically discarded as medical waste following childbirth.

The umbilical cord and the placenta are non-invasive sources of perinatal stem cells.

People who donate stem cells through the peripheral blood stem cell donor procedure report it to be a relativelypainless procedure. Similar to giving blood, the procedure takes about four hours. At a clinic or hospital, an able medical practitioner draws the blood from the donors vein in one of his arms using a needle injection. The technician sends the drawn blood into a machine, which extracts the stem cells. The blood is then returned to the donors body via a needle injected into the other arm. Some patients experience cramping or dizziness, but overall, its considered a painless procedure.

If a blood stem cell donor has a problem with his or her veins, a catheter may be injected in the neck or chest. The donor receives local anesthesia when a catheter-involved donation occurs.

During a bone marrow stem cell donor procedure, the donor is put under heavy sedation in an operating room. The hip is often the site chosen to harvest the bone marrow. More of the desired red marrow is found in flat bones, such as those in the pelvic region. The procedure takes up to two hours, with several extractions made while the patient is sedated. Although the procedure is painless due to sedation, recovery can take a couple of weeks.

Bone marrow stem cell donation takes a toll on the donorbecause it involves the extraction of up to 10 percent of the donors marrow. During the recovery period, the donors body gradually replenishes the marrow. Until that happens, the donor may feel fatigued and sore.

Some clinics offer regenerative and cosmetic therapies using the patients own stem cells derived from the fat tissue located on the sides of the waistline. Considered a simple procedure, clinics do this for therapeutic reasons or as a donation for research.

Stem cells differ from the trillions of other cells in your body. In fact, stem cells make up only a small fraction of the total cells in your body. Some people have a higher percentage of stem cells than others. But, stem cells are special because they are the mothers from which specialized cells grew and developed within us. When these cells divide, they become daughters. Some daughter cells simply self-replicate, while others form new kinds of cells altogether. This is the main way stem cells differ from other body cells they are the only ones capable of generating new cells.

The ways in which stem cells can directly treat patients grow each year. Regenerative medicine now relies heavily on stem cell applications. This type of treatment replaces diseased cells with new, healthy ones generated through donor stem cells. The donor can be another person or the patient themselves.

Sometimes, stem cells also exert therapeutic effects by traveling through the bloodstream to sites that need repair or by impacting their micro-environment through signaling mechanisms.

Some types of adult stem cells, like mesenchymal stem cells (MSCs), are well-known for exerting anti-inflammatory and anti-scarring effects. MSCs can also positively impact the immune system.

Conditions and diseases which stem cell regeneration therapy may help include Alzheimers disease, Parkinsons disease, and multiple sclerosis (MS). Heart disease, certain types of cancer, and stroke victims may also benefit in the future. Stem cell transplant promises advances in treatment for diabetes, spinal cord injury, severe burns, and osteoarthritis.

Researchers also utilize stem cells to test new drugs. In this case, an unhealthy tissue replicates into a larger sample. This method enables researchers to test various therapies on a diseased sample, rather than on an ailing patient.

Stem cell research also allows scientists to study how both healthy and diseased tissue grows and mutates under various conditions. They do this by harvesting stem cells from the heart, bones, and other body areas and studying them under intensive laboratory conditions. In this way, they get a better understanding of the human body, whether healthy or sick.

With the following stem cell transplant benefits, its not surprising people would like to try the therapy as another treatment option.

Physicians harvest stem cell from either the patient or a donor. For an autologous transplant, there is no risk of transferring any disease from another person. For an allogeneic transplant, the donor is meticulously screened before the therapy to make sure they are compatible with the patient and have healthy sources of stem cells.

One common and serious problem of transplants is the risk of rejecting the transplanted organs, tissues, stem cells, and others. With autologous stem cell therapy, the risk is avoided primarily because it comes from the same person.

Because stem cell transplants are typically done through infusion or injection, the complex and complicated surgical procedure is avoided. Theres no risk of accidental cuts and scarring post-surgery.

Recovery time from surgeries and other types of treatments is usually time-consuming. With stem cell therapy, it could only take about 3 months or less to get the patient back to their normal state.

As the number of stem cell treatments dramatically grew over the years, its survival rate also increased. A study published in the Journal of Clinical Oncology showed there was a significant increase in survival rate over 12 years among participants of the study. The study analyzed results from over 38,000 stem cell transplants on patients with blood cancers and other health conditions.

One hundred days following transplant, the researchers observed an improvement in the survival rate of patients with myeloid leukemia. The significant improvements we saw across all patient and disease populations should offer patients hope and, among physicians, reinforce the role of blood stem cell transplants as a curative option for life-threatening blood cancers and other diseases.

With the information above, people now have a better understanding of the answer to the question Where do stem cells come from? Stem cells are a broad topic to comprehend, and its better to go back to its basics to learn its mechanisms. This way, a person can have a piece of detailed knowledge about these master cells from a scientific perspective.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

What do you understand aboutthe basics of stem cells? Share your thoughts in the comments section below.

Up Next:Top 5 TED Talks About Stem Cells

Where Do Stem Cells Come From? | Basics Of Stem Cell Therapy

Continue reading here:
Where Do Stem Cells Come From? | Basics Of Stem Cell ...

Read More...

Types of Stem Cells A Closer Look at Stem Cells

January 31st, 2019 2:44 am

Tissue-specific stem cells

Tissue-specific stem cells (also referred to assomaticoradultstem cells) are more specialized than embryonic stem cells. Typically, these stem cells can generate different cell types for the specific tissue or organ in which they live.

For example, blood-forming (orhematopoietic) stem cells in the bone marrow can give rise to red blood cells, white blood cells and platelets. However, blood-forming stem cells dont generate liver or lung or brain cells, and stem cells in other tissues and organs dont generate red or white blood cells or platelets.

Some tissues and organs within your body contain small caches of tissue-specific stem cells whose job it is to replace cells from that tissue that are lost in normal day-to-day living or in injury, such as those in your skin, blood, and the lining of your gut.

Tissue-specific stem cells can be difficult to find in the human body, and they dont seem to self-renew in culture as easily as embryonic stem cells do. However, study of these cells has increased our general knowledge about normal development, what changes in aging, and what happens with injury and disease.

Here is the original post:
Types of Stem Cells A Closer Look at Stem Cells

Read More...

Stem Cell | Regenerative medicine | 2019 | Conference …

January 29th, 2019 4:44 pm

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contactstemcell@alliedevents.org

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contacts@alliedacademies.com Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

Refund Policy.

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy

Orders are available:

Accommodation Cancellation Policy

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

See original here:
Stem Cell | Regenerative medicine | 2019 | Conference ...

Read More...

Domestic policy of the George W. Bush administration …

January 28th, 2019 5:45 pm

This article discusses the domestic policy of the George W. Bush administration.

Following the September 11 attacks, the Bush Administration proposed and Congress approved, a series of laws stated to be necessary in prosecuting the "War on Terror." These included a wide variety of surveillance programs, some of which came under heavy fire from civil liberties interest groups that criticized the new regulations for infringing upon certain civil liberties. The administration has also been criticized for refusing to back various security measures relating to port security in 2003 and 2004 and vetoing all US$39 million for the 2002 Container Security Initiative.

In early 2001, President Bush worked with Republicans in Congress to pass legislation changing the way the federal government regulated, taxed and funded charities and non-profit initiatives run by religious organizations. Although prior to the legislation it was possible for these organizations to receive federal assistance, the new legislation removed reporting requirements, which required the organizations to separate their charitable functions from their religious functions. Bush also created the White House Office of Faith Based and Community Initiatives.[1] Days into his first term, Bush announced his commitment to channeling more federal aid to faith-based service organizations. Bush created the Office of Faith-Based and Community Initiatives to assist faith-based service organizations. Critics claimed that this was an infringement of the separation of church and state.[2][3]

As Governor of Texas, Bush had opposed efforts to repeal the criminal prohibition on "homosexual conduct", the same law that the United States Supreme Court overturned in 2003, Lawrence v. Texas. During the 2000 campaign he did not endorse a single piece of gay rights legislation, although he did meet with an approved group of Log Cabin Republicans, a first for a Republican presidential candidate.[4]

In his first four years of office, his views on gay rights were often difficult to ascertain, but many experts feel that the Bush White House wanted to avoid bad publicity without alienating evangelical conservative Christian voters. Thus, he did not repeal President Clinton's Executive Order banning discrimination based on sexual orientation in the federal civilian government, but its critics felt it was ignored.[5] He did not attempt to repeal Don't ask, don't tell, nor try to change it. He threatened to veto the Matthew Shepard Act, which would have included sexual orientation in hate crimes.

While President Bush had always been on record as opposing the legal recognition of same-sex marriages, the 2004 Republican campaign strategy was to focus on "value issues" such as a Federal Marriage Amendment, that would prohibit same-sex couples from obtaining any legal recognition. President Bush endorsed this proposed amendment, but late in the campaign told ABC News and Larry King that he did not have a problem with state legislators enacting some type of civil unions legislation, although critics charged that the constitutional amendment he endorsed did not permit recognition of such unions.

Bush still expressed support for the Federal Marriage Amendment in his February 2, 2005 State of the Union addressand during the 2006 midterm election, but given that it did not even receive majority support in the Senate, has ignored this issue in his most recent public statements and speeches.

Bush was the first Republican president to appoint an openly gay man to serve in his administration, Scott Evertz, as director of the Office of National AIDS Policy.[6] In addition, during Bush's first term, his nominee as ambassador to Romania, Michael E. Guest, became the first openly gay man to be confirmed by the Senate as a U.S. ambassador. The first openly gay ambassador, James Hormel, received a recess appointment from Bill Clinton after the Senate failed to confirm the nomination.

According to a CNN exit poll, Bush's support from African-Americans increased during his presidency from 9% of the black vote in 2000 to 11% in 2004.[7] An increase in Ohio (from 9% to 16%,[7] each about 5%) may have helped give the victory to Bush over Kerry.

Although Bush expressed appreciation for the Supreme Court's ruling upholding the selection of college applicants for purposes of diversity, his Administration filed briefs against it. Bush has said he opposes government sanctioned and enforced quotas and racial preferences, but that the private and public sector should be encouraged to reach out to accomplished minorities to increase employment diversity.

In August 2005, a report by the United States Commission on Civil Rights states that "the government fails to seriously consider race-neutral alternatives as the Constitution requires."[8] Chairman Gerald A. Reynolds explained, "Federal agencies do not independently evaluate, conduct research, collect data, or periodically review programs to determine whether race-neutral strategies will provide an adequate alternative to race-conscious programs." Civil rights groups expressed concern that the report was an attack on affirmative action inconsistent with Grutter v. Bollinger.

In his first term, Bush appointed Colin Powell as Secretary of State. Powell was the first African-American man to serve in that position, and was succeeded by Condoleezza Rice: Rice became the first African-American woman to hold the post. In 2005, he appointed Alberto Gonzales as the United States Attorney General, the first Hispanic to hold that position.

Bush met with the National Urban League, the nation's oldest civil rights organization during his term of office as well.

President George W. Bush signed into law the Genetic Information Nondiscrimination Act (GINA).[9][10] The bill protects Americans against discrimination based on their genetic information when it comes to health insurance and employment. The issue had been debated for 13 years before becoming law. It is designed to protect citizens while not hindering genetic research.

On December 19, 2002, Bush signed into law H. R. 4664, far-reaching legislation to put the National Science Foundation (NSF) on a track to double its budget over five years and to create new mathematics and science education initiatives at both the pre-college and undergraduate level.[11] In the first three years of those five, the R&D budget has increased by fourteen percent.[12][13] Bush has long been dogged by criticism that his administration ignores or suppresses scientific advice.[14] Bush showed support for oceanography and space exploration; and supported sciences on reducing pollution. Bush generally was opposed to biology especially the science of human reproduction and reproductive health; and science with global warming. Bush supported "Teach the Controversy". Bush's positions were not always shared by his party.

President Bush supported adult stem cell research and umbilical cord blood stem cell research. However, Bush opposed any new embryonic stem cell research, and had limited the federal funding of existing research. Federal funding for embryonic stem cell research was first approved under President Clinton on January 19, 1999,[citation needed] but no money was to be spent until the guidelines were published. The guidelines were released under Clinton on August 23, 2000.[citation needed] They allowed use of unused frozen embryos. On August 9, 2001, before any funding was granted under these guidelines, Bush announced modifications to the guidelines to allow use of only existing stem cell lines.[15] While Bush claimed that more than 60 embryonic stem cell lines already existed from privately funded research, scientists in 2003 said there were only 11 usable lines, and in 2005 that all lines approved for Federal funding are contaminated and unusable.[16] Adult stem cell funding was not restricted and was supported by President Bush as a more viable means of research.

On January 14, 2004, Bush announced a Vision for Space Exploration,[17] calling for the completion of the International Space Station by 2010 and the retirement of the space shuttle while developing a new spacecraft called the Crew Exploration Vehicle under the title Project Constellation. The CEV would be used to return American astronauts to the Moon by 2018, with the objective of establishing a permanent lunar base, and eventually sending future manned missions to Mars.[18] To this end, the plan proposes that NASA's budget increase by five percent every year until it is capped at US$18 billion in 2008, with only inflationary increases thereafter.[19] The planned retirement of the Space Shuttle fleet in 2010 after the ISS is completed is also expected to free up US$5 billion to US$6 billion a year. The US$16.2 billion budget for 2005 proposed by NASA met with resistance from House and Senate spending committees, and the initiative was little-mentioned during the presidential campaign.[20] Nonetheless, the budget was approved with only minor changes shortly after the November elections.

Supporters believe that this plan will be an important part of what Bush set in place while in office. However, the policy has been criticized on two fronts. Firstly, critics have opined that the United States should deal with solving domestic issues before concentrating on space exploration. Secondly, of the funding over the next five years that Bush has proposed, only US$1 billion will be in new appropriations while the remaining US$11 billion will be reallocated from NASA's other programs, and therefore inadequate to fully realize this vision. Most of the spending for the new program, and most of the budget cuts for existing programs, are scheduled after the last year of the Bush presidency. It is unclear how the space vision will be reconciled with budgetary concerns in the longer term.

In January 2005, the White House released a new Space Transportation Policy fact sheet[21] which outlined the administration's space policy in broad terms and tied the development of space transport capabilities to national security requirements.

In December 2003, Bush signed legislation implementing key provisions of his Healthy Forests Initiative. Another subject of controversy is Bush's Clear Skies Initiative, which seeks to reduce air pollution through expansion of emissions trading.

Bush signed the Great Lakes Legacy Act of 2002 authorizing the federal government to begin cleaning up pollution and contaminated sediment in the Great Lakes, as well as the Brownfields Legislation in 2002, accelerating the cleanup of abandoned industrial sites, or brownfields, to better protect public health, create jobs, and revitalize communities.

Bush stated his reason for not supporting the Kyoto Protocol was that it unfairly targeted the United States while being deliberately lenient with certain developing countries, especially China and India. Bush stated, "The world's second-largest emitter of greenhouse gases is China. Yet, China was entirely exempted from the requirements of the Kyoto Protocol."

Bush also questioned the science behind the global warming phenomenon, insisting that more research be done to determine its validity.[22]

Upon arriving in office in 2001, President Bush withdrew United States support of the then-pending Kyoto Protocol, a UN Convention seeking to impose mandatory targets for reducing "greenhouse gas" emissions. Bush stated that human activity had not been proven to be the cause and cited concerns about the treaty's impact on the U.S. economy and pointed out that China and India had not signed on.[23] The Protocol entered into force on 16 February 2005. As of September 2011, 191 states have signed and ratified the protocol.[24] The only remaining signatory not to have ratified the protocol is the United States.

In 2002, the Bush Administration's EPA issued a Climate Action Report concluding that the climate changes observed over several decades "are likely mostly due to human activities, but we cannot rule out that some significant part of these changes is also a reflection of natural variability".[25] While the EPA report was initially hailed by some environmentalists critical of the Bush administration as a "180-degree turn on the science" reversing "everything the president has said about global warming since he took office," within days President Bush dismissed the report as being "put out by the bureaucracy," and reaffirmed his opposition to the Kyoto Protocol.[25]

The Bush Administration's stance on global warming, and in particular its questioning the consensus of scientists, would remain controversial in the scientific and environmental communities during his presidency. In 2004, the Director of NASA's Goddard Institute, James E. Hansen, came out publicly and harshly accusing the Administration of misinforming the public by suppressing the scientific evidence of the dangers of greenhouse gases, saying the Bush Administration wanted to hear only scientific results that "fit predetermined, inflexible positions" and edited reports to make the dangers sound less threatening in what he asserted was "direct opposition to the most fundamental precepts of science."[26][27] Other experts, such as former U.S. Department of Energy official Joseph Romm, have decried the Bush administration as a "denier and delayer" of government action essential to reduce carbon emissions and deter global warming.[28]

In 2005, Council on Environmental Quality chairman and former oil industry lobbyist Philip Cooney, was accused of doctoring and watering down descriptions of climate research from other government agencies. The White House denied these reports.[29] Two days later, Cooney announced his resignation[30] and conceded his role in altering the reports. "My sole loyalty was to the President and advancing the policies of his administration," he told the United States House Committee on Oversight and Government Reform.[31][32]

In addition, the administration thanked Exxon executives for the company's "active involvement" in helping to determine climate change policy, including the US stance on Kyoto.[33]

President Bush believes that global warming is real[34] and has said that he has consistently noted that global warming is a serious problem but asserted there is a "debate over whether it's manmade or naturally caused" and maintained that regardless of that debate his administration was working on plans to make America less dependent on foreign oil "for economic and national security reasons."[35]

The United States has signed the Asia Pacific Partnership on Clean Development and Climate, a pact that allows signatory countries to set goals for reducing greenhouse gas emissions individually, but with no enforcement mechanism. Republican Governor Arnold Schwarzenegger, along with 187 mayors from US towns and cities, have pledged to adopt Kyoto style legal limits on greenhouse gas emissions.[36]

For economic and national security reasons, Bush supported Alaska Senator Ted Stevens' plan to tap the oil reserves in a 2,000-acre (8km2) area of Alaska's 19 million acre (77,000km) Arctic National Wildlife Refuge. Pro-exploration supporters argue that U.S. companies have the most stringent environmental requirements, and that by doing the drilling in the middle of the winter, it would create a very small environmental footprint.[37]

Opponents stated that drilling would damage the coastal plain's fragile ecosystem and its wildlife. Proponents stated that modern techniques can extract the oil without damaging the environment [38]

Initially announced by President Bush in 2002,[39] the Clear Skies Initiative was aimed at amending the Clean Air Act to further reduce air pollution and expanded the emissions trading programs to include new pollutants such as mercury. The goal of the initiative was to reduce the sulfur dioxide, nitrogen oxide, and mercury emissions of power plants over the course of 15 years, while saving consumers millions of dollars.[39]

Among other things, the Clear Skies Act states that it would:[40][41][42]

The Natural Resources Defense Council, and its more than 500,000 members, examined the administration proposal and concluded it would harm public health, weaken current pollution fighting programs and worsen global warming. S. 385, the administration's bill to amend the Clean Air Act would:1. Allow power plant pollution to continue to inflict huge, avoidable health damages on the public. 2. Repeal or interfere with major health and air quality safeguards in current law. 3. Worsen global warming by ignoring CO2 emissions from the power sector.[43]

In January 2002, Bush signed the No Child Left Behind Act, with Democratic Senator Ted Kennedy as chief sponsor,[44] which aims to close the achievement gap, measures student performance, provides options to parents with children in low-performing schools, and targets more federal funding to low-income schools. Critics, including Senator John Kerry and the National Education Association, say schools were not given the resources to help meet new standards, although their argument is based on premise that authorization levels are spending promises instead of spending caps. The House Committee on Education and the Workforce said that the Department of Education's overall funding increased by US$14 billion since the enactment of NCLB in fiscal year 2001, going from US$42.6 billion to US$56.6 billion in fiscal year 2005.[citation needed] Some state governments are refusing to implement provisions of the act as long as they are not adequately funded.[45]

In January 2005, USA Today reported that the United States Department of Education had paid US$240,000 to African-American conservative political commentator Armstrong Williams "to promote the law on his nationally syndicated television show and to urge other black journalist to do the same."[46] Williams did not disclose the payments.

The House Education and Workforce Committee stated, "As a result of the No Child Left Behind Act, signed by Bush on January 8, 2002, the Federal government today is spending more money on elementary and High School (K-12) education than at any other time in the history of the United States.[citation needed] Funding increases have to a large degree been offset at the state level by increased costs associated with implementing NCLB, as well as the impacts of the economic downturn on education budgets.

According to the National Bureau of Economic Research, the economy suffered from a recession that lasted from March 2001 to November 2001. During the Bush Administration, Real GDP has grown at an average annual rate of 2.5%.[47]

Inflation under Bush has remained near historic lows at about 2-3% per year. The recession and a drop in some prices led to concern about deflation from mid-2001 to late 2003. More recently, high oil prices have caused concern about increasing inflation.

Long-term problems include inadequate investment in economic infrastructure, rapidly rising medical and pension costs of an aging population, sizable trade and budget deficits. Under the Bush administration, productivity has grown by an average of 3.76% per year, the highest such average in ten years.[48]

While the GDP recovered from a recession that some claim Bush inherited from the previous administration,[49] poverty has since worsened according to the Census Bureau. The percentage of the population below the poverty level increased in each of Bush's first four years, while it decreased for each of the prior seven years to an 11-year low. Although the poverty level increased the increase was still lower from 2000 to 2002 than it was from 1992 to 1997, which reached a peak of 39.3% in 1993. In 2002 the poverty rate was 34.6% which was almost equal to the rate in 1998, which was 34.5%. Poverty was at 12.7% in 2004.[citation needed]

President Bush won passage for two major tax cuts during his term in office: The Economic Growth and Tax Relief Reconciliation Act of 2001 and the Jobs and Growth Tax Relief Reconciliation Act of 2003. Collectively, they became known, analyzed, and debated as the "Bush tax cuts".

The cuts, scheduled to expire a decade after passage, increased the standard income tax deduction for married couples, eliminated the estate tax, and reduced marginal tax rates. Bush asked Congress to make the tax cuts permanent, but others wanted the cuts to be wholly or partially repealed even before their scheduled expiration, seeing the decrease in revenue while increasing spending as fiscally irresponsible.

Bush's supporters claim that the tax cuts increase the pace of economic recovery and job creation. They also claim that total benefits to wealthier individuals are a reflection of higher taxes paid. Individual income tax rate provisions in the 2001 law, for instance, created larger marginal tax rate decreases for people earning less than US$12,000 than any other earners.[50]

His opponents contest job prediction claims, primarily noting that the increase in job creation predicted by Bush's plan failed to materialize. They instead allege that the purpose of the tax cuts was intended to favor the wealthy and special interests, as the majority of benefit from the tax cut, in absolute terms, went to earners in the higher tax brackets. Bush's opponents additionally claim that the tax cuts are a major reason Bush reversed a national surplus into a historically large deficit.

In an open letter to Bush in 2004, more than 100 professors of business and economics at U.S. business schools ascribed this "fiscal reversal" to Bush's "policy of slashing taxes - primarily for those at the upper reaches of the income distribution."[51]

By 2004, these cuts had reduced federal tax revenues, as a percentage of the Gross Domestic Product, to the lowest level since 1959. With the NASDAQ crash and one quarter of negative growth in 2000 it was likely we were headed into a recession,[52] yet merely two years after the 2003 Bush tax cuts, federal revenues (in dollars) had reached a record high.[53] The effect of simultaneous record increases in spending and tax reductions was to create record budget deficits in absolute terms, though as recently as 1993, the deficit was slightly larger than the current 3.6% of the GDP. In the last year of the Clinton administration, the federal budget showed an annual surplus of more than US$230 billion.[54] Under Bush, the government returned to deficit spending. The annual deficit reached an absolute record of US$374 billion in 2003 and then a further record of $413 billion in 2004.[55][56]

President Bush expanded public spending by 70 percent, more than double the increase under President Clinton. Bush was the first president in 176 years to continue an entire term without vetoing any legislation.[57]

The tax cuts, recession, and increases in outlays all contributed to record budget deficits during the Bush administration. The annual deficit reached record current-dollar levels of US$374 billion in 2003 and US$413 billion in 2004. National debt, the cumulative total of yearly deficits, rose from US$5.7 trillion (58% of GDP) to US$8.3 trillion (67% of GDP) under Bush,[citation needed] as compared to the US$2.7 trillion total debt owed when Ronald Reagan left office, which was 52% of the GDP.[58]

According to the "baseline" forecast of federal revenue and spending by the Congressional Budget Office (in its January 2005 Baseline Budget Projections),[59] the budget deficits will decrease over the next several years. In this projection the deficit will fall to US$368 billion in 2005, US$261 billion in 2007, and US$207 billion in 2009, with a small surplus by 2012. The CBO noted, however, that this projection "omits a significant amount of spending that will occur this year and possibly for some time to come for U.S. military operations in Iraq and Afghanistan and for other activities related to the global War on Terrorism." The projection also assumes that the Bush tax cuts "will expire as scheduled on December 31, 2010." If, as Bush has urged, the tax cuts were to be extended, then "the budget outlook for 2015 would change from a surplus of US$141 billion to a deficit of US$282 billion." Other economists have disputed this, arguing that the CBO does not use dynamic scoring, to take into account what effect tax cuts would have on the economy.

Federal spending in constant dollars increased under Bush by 26% in his first four and a half years. Non-defense spending increased 18% in that time.[60] Of the US$2.4 trillion budgeted for 2005, about US$450 billion are planned to be spent on defense. This level is generally comparable to the defense spending during the cold war.[citation needed] Congress approved US$87 billion for Iraq and Afghanistan in November, and had approved an earlier US$79 billion package last spring. Most of those funds were for U.S. military operations in the two countries.

Former President Clinton's last budget featured an increase of 16% on domestic non security discretionary spending. Growth under President Bush was cut to 6.2% in his first budget, 5.5% in his second, 4.3% in his third, and 2.2% in his fourth.

Bush supports free trade policies and legislation but has resorted to protectionist policies on occasion. Tariffs on imported steel imposed by the White House in March 2002 were lifted after the World Trade Organization ruled them illegal. Bush explained that the safeguard measures had "achieved their purpose", and "as a result of changed economic circumstances", it was time to lift them.[61]

President Bush signed a large number of free trade agreements into law during his Presidency: Jordan (2001), Singapore and Chile (2004), Australia (2005), Dominican Republic, CAFTA, Morocco, Oman, and Bahrain (2006), and Oman and Peru (2009).

The Bush administration also launched trade negotiations with New Zealand, Thailand, Kuwait, Malaysia, Qatar, South Korea, Colombia, and Panama, with some being completed during President Obama's first term in office (2009-2013).

Some say economic regulation expanded rapidly during the Bush administration. President Bush is described by these observers as the biggest regulator since President Richard Nixon.[62] Bush administration increased the number of new pages in the Federal Registry, a proxy for economic regulation, from 64,438 new pages in 2001 to 78,090 in new pages in 2007, a record amount of regulation.[62] Economically significant regulations, defined as regulations which cost more than $100 million a year, increased by 70%.[62]

Spending on regulation increased by 62% from $26.4 billion to $42.7 billion.[62]

The contrary view on Bush's regulatory record is that he discouraged regulators from enforcing regulations and that counting pages in the Federal Register is a myopic method of measuring an administration's regulatory stance. The 2008 financial crisis occurred near the end of the Bush second term and represented an enormous failure for financial deregulation.[63]

Looking at the annual average unemployment rates for each of the eight years of Bush's presidency, the average of all eight figures, and thus of his entire presidency, is 5.26%, with a low of 4.6% for the years of 2006 and 2007, and a high of 6.0% for 2003.[64]

According to the Bureau of Labor Statistics, the number of unemployed was nearly 6.0 million in January 2001 and 6.9 million in September 2006. The unemployment rate was 4.2% in January 2001, 4.6% in September 2006, and 7.2% in December 2008. Employment peaked in late 1999 and declined through 2008.[65]

The Current Population Survey (aka Household Survey) measures the percentage of the population that is employed and unemployed. The result can be multiplied by population estimates to get total employment estimates. This survey has the advantage over the payroll survey in that it includes self-employed. The Household Survey is less accurate in producing total numbers since it requires population estimates and in that it samples many fewer people (60,000 households versus 400,000 business establishments). For better or worse, the Household Survey counts multiple jobs held by one person only once, and it includes government workers, farm workers, unpaid family workers, and workers absent without pay. The Household Survey indicates that the percentage of the population employed decreased from 64.4% in December 2000 and January 2001 to 62.1% in August and September 2003. By August 2005, it had recovered only to 62.9%. In absolute numbers, this corresponds to a drop of 1.6 million jobs but an eventual net gain of 4.7 million jobs during the Bush administration.[66]Private sector employment, as measured by private nonfarm payrolls, shrank over the 8 years of the George W. Bush presidency. There were modest gains in private-sector payroll employment during his first term, but these were more than offset by the shedding of workers by the private sector in his second term. There were 463,000 fewer private-sector payroll jobs when he left office than when he came into office.[67]

In 2004, a full chapter on Iraq's economy was excised from the Economic Report of the President, in part because it doesn't fit the "feel good" tone of the writing, according to White House officials.[citation needed]

In July 2002, Bush cut off U.S. funding to the United Nations Population Fund (UNFPA). Bush stated that the UNFPA supported forced abortions and sterilizations in the People's Republic of China.[68]

Bush signed the Medicare Act of 2003, which added prescription drug coverage to Medicare (United States), subsidized pharmaceutical corporations, and prohibited the Federal government from negotiating discounts with drug companies.

Bush signed the Partial-Birth Abortion Ban Act in 2003, having declared his aim to "promote a culture of life".

Bush is an advocate of the partial privatization of Social Security wherein an individual would be free to invest a portion of his Social Security taxes in personal retirement accounts.

Bush has called for major changes in Social Security, identifying the system's projected insolvency as a priority early in his second term. From January through April 2005, he toured the country, stopping in over 50 cities across the nation warning of an impending "crisis". Initially, President Bush emphasized his proposal for personalized accounts would allow individual workers to invest a portion of their Social Security Tax (FICA) into secured investments. The main advantage of personal accounts within Social Security is to allow workers to own the money they place into retirement that cannot be taken away by political whims.

Most Democrats and some Republicans are critical of such ideas, partly because of the large (US$1 trillion or more) federal borrowing the plan would require, which might actually worsen the imbalance between revenues and expenses that Bush pointed to as a looming problem; and partly because of the problems encountered by the United Kingdom's privatized pension plan. See Social Security debate (United States). In addition, many Democrats opposed changes that they felt were turning Social Security into a welfare program that would be politically vulnerable. Portions of Bush's bill exempting private companies from social security payments have led to complaints that Bush's plan was created to benefit private companies, and that it would turn Social Security into just another insurance program.

George W. Bush is a strong supporter of capital punishment. During his tenure as Governor of Texas, 152 people were executed in that state, maintaining its record as the leading state in executions.[69] As President of the United States, he has continued in his support for capital punishment, including presiding over the first federal execution in decades, that of convicted terrorist Timothy McVeigh. Although Bush's support of the death penalty is known, controversy broke in 1999 when journalist Tucker Carlson revealed that the Governor had mocked the plight of Karla Faye Tucker in an interview.

On his first day in office, President Bush implemented the Mexico City Policy; this policy required nongovernmental organizations receiving federal funds to agree not to perform abortions or to actively promote abortion as a method of family planning in other nations.[70][71] In 2002, President Bush signed the Born-Alive Infants Protection Act, which extends legal protection to infants born alive after failed attempts at induced abortion.[72] Also in 2002, President Bush withdrew funding from the United Nations Population Fund based on a finding that UNPF's activities facilitated China's one-child-only/forced abortion policy.[73] In 2003, President Bush signed the Partial Birth Abortion Ban Act into law;[74] that law was later upheld by the Supreme Court of the United States in Gonzales v. Carhart.[75] President Bush signed the Unborn Victims of Violence Act (Laci and Conner's Law), which provides that a person who commits certain federal violent crimes and thereby causes the death of, or bodily injury to, a fetus shall be guilty of a separate offense, whether or not the person knew the mother was pregnant or intended to harm the fetus.[76]

Bush staunchly opposes euthanasia. He supported Ashcroft's decision to file suit against the voter-approved Oregon Death with Dignity Act, which was ultimately decided by the Supreme Court in favor of the Oregon law.[77] As governor of Texas, however, Bush had signed a law which gave hospitals the authority to take terminally ill patients off of life support against the wishes of their spouse or parents, if the doctors deemed it medically appropriate.[78] This became an issue in 2005, when the President signed controversial legislation forwarded and voted on by only three members of the Senate to initiate federal intervention in the Terri Schiavo case.[79]

Bush signed the Amber Alert legislation into law on April 30, 2003, which was developed to quickly alert the general public about child abductions using various media sources.[80] On July 27, 2006 Bush signed the Adam Walsh Child Protection and Safety Act which establishes a national database requiring all convicted sex offenders to register their current residency and related details on a monthly instead of the previous yearly basis. Newly convicted sex offenders will also face longer mandatory incarceration periods.[81]

On June 15, 2006, Bush created the seventy-fifth, and largest, National Monument in U.S. history and the largest Marine Protected Area in the world with the formation of the Northwestern Hawaiian Islands National Monument.[82]

The Prison Rape Elimination Act of 2003 (PREA) is the first United States federal law passed dealing with the sexual assault of prisoners. The bill was signed into law on September 4, 2003. As a result, the National Prison Rape Elimination Commission was created to study the problem and recommend solutions. Federal funding for prisons also began to require detainment facilities to keep records on sexual assault. Failure to follow PREA requirements resulted in losing up to 5% of funding. New grants to prevent sexual assault were also created by the law. Significant support for the act came from Human Rights Watch, Concerned Women for America, Just Detention International, and numerous evangelical organizations.

In 2005-06, Bush emphasized the need for comprehensive energy reform and proposed increased funding for research and development of renewable sources of energy such as hydrogen power, nuclear power, ethanol, and clean coal technologies. Bush proposed the American Competitiveness Initiative which seeks to support increasing competitiveness of the U.S. economy, with greater development of advanced technologies, as well as greater education and support for American students. In the 2007 State of the Union speech, President Bush proposed a 20:10 policy, where, as a nation, the United States would be working to reduce 20% of the national energy usage in next 10 years by converting to ethanol.

Bush's imposition of a tariff on imported steel and on Canadian softwood lumber was controversial in light of his advocacy of free market policies in other areas. The steel tariff was later rescinded under pressure from the World Trade Organization. A negotiated settlement to the softwood lumber dispute was reached in April 2006, and the historic seven-year deal was finalized on July 1, 2006.[citation needed]

Go here to see the original:
Domestic policy of the George W. Bush administration ...

Read More...

Samples of Formatted References for Authors of Journal …

January 28th, 2019 5:44 pm

The International Committee of Medical Journal Editors (ICMJE) offers guidance to authors in its publication Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations), which was formerly the Uniform Requirements for Manuscripts. The recommended style for references is based on the National Information Standards Organization NISO Z39.29-2005 (R2010) Bibliographic References as adapted by the National Library of Medicine for its databases.

Details, including fuller citations and explanations, are in Citing Medicine. (Note Appendix F which covers how citations in MEDLINE/PubMed differ from the advice in Citing Medicine.) For datasets (Item 43 below) and software on the Internet (Item 44 below), simplified formats are also shown.

See also #36. Journal article on the Internet and #43. Dataset description article.

1. Standard journal article

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002 Jul 25;347(4):284-7.

List the first six authors, followed by et al. If there are more than six authors, list the first six authors, followed by et al. (Note: NLM now lists all authors.):

Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.

Optional: If a journal carries continuous pagination throughout a volume (as many medical journals do), omit the month and issue number.

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

Optional: Addition of a database's unique identifiers, such as the PubMed PMID, for the citation:

Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol. 2009 Feb;127(2):179-86. PubMed PMID: 19204236; PubMed Central PMCID: PMC2653214.

Optional: Addition of a clinical trial registration number:

Trachtenberg F, Maserejian NN, Soncini JA, Hayes C, Tavares M. Does fluoride in compomers prevent future caries in children? J Dent Res. 2009 Mar;88(3):276-9. PubMed PMID: 19329464. ClinicalTrials.gov registration number: NCT00065988.

2. Organization as author

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679-86.

3. Both personal authors and organization as author (List all as they appear in the byline.)

Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169(6):2257-61.

4. No author given

21st century heart solution may have a sting in the tail. BMJ. 2002;325(7357):184.

5. Article not in English

Ellingsen AE, Wilhelmsen I. Sykdomsangst blant medisin- og jusstudenter. Tidsskr Nor Laegeforen. 2002;122(8):785-7. Norwegian.

Optional: Translation of article title (MEDLINE/PubMed practice):

Ellingsen AE, Wilhelmsen I. [Disease anxiety among medical students and law students]. Tidsskr Nor Laegeforen. 2002 Mar 20;122(8):785-7. Norwegian.

6. Volume with supplement

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.

7. Issue with supplement

Glauser TA. Integrating clinical trial data into clinical practice. Neurology. 2002;58(12 Suppl 7):S6-12.

8. Volume with part

Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. Int J Psychoanal. 2002;83(Pt 2):491-5.

9. Issue with part

Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumors. J Vasc Interv Radiol. 2002;13(9 Pt 1):923-8.

10. Issue with no volume

Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. Clin Orthop. 2002;(401):230-8.

11. No volume or issue

Outreach: bringing HIV-positive individuals into care. HRSA Careaction. 2002 Jun:1-6.

12. Pagination in roman numerals

Chadwick R, Schuklenk U. The politics of ethical consensus finding. Bioethics. 2002;16(2):iii-v.

13. Type of article indicated as needed

Tor M, Turker H. International approaches to the prescription of long-term oxygen therapy [letter]. Eur Respir J. 2002;20(1):242.

Lofwall MR, Strain EC, Brooner RK, Kindbom KA, Bigelow GE. Characteristics of older methadone maintenance (MM) patients [abstract]. Drug Alcohol Depend. 2002;66 Suppl 1:S105.

14. Article containing retraction

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002;63(2):169. Retraction of: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2000;61(12):909-11.

Article containing a partial retraction:

Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction after removal of eroded slings. J Urol. 2006 Dec;176(6 Pt 1):2749. Partial retraction of: Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Sep;176(3):1040-4.

15. Article retracted

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2000;61(12):909-11. Retraction in: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2002;63(2):169.

Article partially retracted:

Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction following removal of eroded synthetic mid urethral slings. J Urol. 2006 Sep;176(3):1040-4. Partial retraction in: Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Dec;176(6 Pt 1):2749.

16. Article republished with corrections

Mansharamani M, Chilton BS. The reproductive importance of P-type ATPases. Mol Cell Endocrinol. 2002;188(1-2):22-5. Corrected and republished from: Mol Cell Endocrinol. 2001;183(1-2):123-6.

17. Article with published erratum

Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000;22(10):1151-68; discussion 1149-50. Erratum in: Clin Ther. 2001;23(2):309.

18. Article published electronically ahead of the print version

Yu WM, Hawley TS, Hawley RG, Qu CK. Immortalization of yolk sac-derived precursor cells. Blood. 2002 Nov 15;100(10):3828-31. Epub 2002 Jul 5.

Back to top of page

19. Personal author(s)

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.

20. Editor(s), compiler(s) as author

Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

21. Author(s) and editor(s)

Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. White Plains (NY): March of Dimes Education Services; 2001.

22. Organization(s) as author

American Occupational Therapy Association, Ad Hoc Committee on Occupational Therapy Manpower. Occupational therapy manpower: a plan for progress. Rockville (MD): The Association; 1985 Apr. 84 p.

National Lawyer's Guild AIDs Network (US); National Gay Rights Advocates (US). AIDS practice manual: a legal and educational guide. 2nd ed. San Francisco: The Network; 1988.

23. Chapter in a book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

24. Conference proceedings

Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

25. Conference paper

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

26. Scientific or technical report

Issued by funding/sponsoring agency:

Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK). Health monitoring on vibration signatures. Final report. Arlington (VA): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.

Issued by performing agency:

Russell ML, Goth-Goldstein R, Apte MG, Fisk WJ. Method for measuring the size distribution of airborne Rhinovirus. Berkeley (CA): Lawrence Berkeley National Laboratory, Environmental Energy Technologies Division; 2002 Jan. Report No.: LBNL49574. Contract No.: DEAC0376SF00098. Sponsored by the Department of Energy.

27. Dissertation

Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.

28. Patent

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.

Back to top of page

29. Newspaper article

Tynan T. Medical improvements lower homicide rate: study sees drop in assault rate. The Washington Post. 2002 Aug 12;Sect. A:2 (col. 4).

30. Audiovisual material

Chason KW, Sallustio S. Hospital preparedness for bioterrorism [videocassette]. Secaucus (NJ): Network for Continuing Medical Education; 2002.

31. Legal Material

Public law:Veterans Hearing Loss Compensation Act of 2002, Pub. L. No. 107-9, 115 Stat. 11 (May 24, 2001).

Unenacted bill:Healthy Children Learn Act, S. 1012, 107th Cong., 1st Sess. (2001).

Code of Federal Regulations:Cardiopulmonary Bypass Intracardiac Suction Control, 21 C.F.R. Sect. 870.4430 (2002).

Hearing:Arsenic in Drinking Water: An Update on the Science, Benefits and Cost: Hearing Before the Subcomm. on Environment, Technology and Standards of the House Comm. on Science, 107th Cong., 1st Sess. (Oct. 4, 2001).

32. Map

Pratt B, Flick P, Vynne C, cartographers. Biodiversity hotspots [map]. Washington: Conservation International; 2000.

33. Dictionary and similar references

Dorland's illustrated medical dictionary. 29th ed. Philadelphia: W.B. Saunders; 2000. Filamin; p. 675.

Back to top of page

34. Forthcoming and Preprints

Go here to read the rest:
Samples of Formatted References for Authors of Journal ...

Read More...

Page 906«..1020..905906907908..920930..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick